Diabetes Education and Care for Deaf Populations

April 7, 2025 updated by: Michelle Litchman, University of Utah

Improving Access to Diabetes Education and Care for Deaf Populations

This study will assess the feasibility and preliminary efficacy of a 10-week intervention called "Deaf Diabetes Can Together".

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • University of Utah

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Identify as Deaf/Hard of Hearing
  • living with diabetes (any type)
  • speak and understand English or American Sign Language
  • have access to internet
  • willing to participate in the intervention

Exclusion Criteria:

  • participating in another diabetes study
  • have significant cognitive impairment
  • are pregnant or planning to become pregnant in the next year
  • have life expectancy of <6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Deaf Diabetes Can Together
Behavioral: Deaf Diabetes Can Together
10-week diabetes self-management telehealth intervention for deaf adults with diabetes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A1C Level
Time Frame: 6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)
Clinical outcome
6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diabetes Distress Level Using the Screening Scale Questionnaire
Time Frame: 6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)
Psychosocial outcome, scoring averaged from 1-6 with higher score means worse outcome.
6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)
Diabetes Self-Care Level using the Self-Care Inventory Revised Questionnaire
Time Frame: 6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)
Self-management outcome, scoring averaged from 0-100 point scale with higher score means better outcome.
6 months: (Test at 0 weeks, 12 weeks, and 24 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Utah

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 17, 2023

Primary Completion (Actual)

July 22, 2024

Study Completion (Actual)

September 1, 2024

Study Registration Dates

First Submitted

November 7, 2023

First Submitted That Met QC Criteria

August 26, 2024

First Posted (Actual)

August 29, 2024

Study Record Updates

Last Update Posted (Actual)

April 10, 2025

Last Update Submitted That Met QC Criteria

April 7, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 00151575

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe